LSA
BCYC

L & S Advisors’s Bicycle Therapeutics BCYC Stock Holding History

L & S Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-59,735
Closed -$1.35M – 340
2024
Q3 		$1.35M Buy
59,735
+1,400
+2% +$32.3K 0.14% 163
2024
Q2 		$1.18M Buy
58,335
+8,075
+16% +$182K 0.13% 169
2024
Q1 		$1.25M Buy
50,260
+40,070
+393% +$851K 0.14% 172
2023
Q4 		$184K Buy
+10,190
New +$169K 0.02% 311
2023
Q1 		– Sell
-34,950
Closed -$1.03M – 307
2022
Q4 		$1.03M Sell
34,950
-7,815
-18% -$210K 0.19% 119
2022
Q3 		$995K Buy
+42,765
New +$1.02M 0.18% 123

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

L & S Advisors's BCYC Position: Q4 2024 in Review

L & S Advisors sold out of Bicycle Therapeutics (BCYC) in Q4 2024, closing a stake of 59,735 shares — an estimated $1.35M sold.

L & S Advisors first reported a position in BCYC in Q3 2022 and held it in 6 quarters. The position peaked at $1.35M in Q3 2024. 97 funds tracked by Wall St. Rank hold BCYC as of Q4 2024.

  • L & S Advisors reported no remaining Bicycle Therapeutics position as of Q4 2024 after selling out during the quarter.
  • L & S Advisors sold 59,735 Bicycle Therapeutics shares in Q4 2024, an estimated $1.35M.
  • L & S Advisors first reported a position in Bicycle Therapeutics in Q3 2022 and held it in 6 quarters.
  • L & S Advisors's Bicycle Therapeutics position peaked at $1.35M in Q3 2024.
  • 97 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2024.

Based on L & S Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.